Safety and effectiveness of Daromun injections for advanced melanoma
This trial is studying the safety and effectiveness of a drug called Daromun, which is injected directly into melanoma tumors. It's for people with advanced melanoma who have already received at least one Daromun injection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have melanoma that started in the skin or with no known primary site (not in the eye or mucous membranes).
- Your melanoma is stage IIIB, IIIC, or IIID (locally advanced).
- Your melanoma got worse after immunotherapy, or you cannot have immunotherapy for medical reasons.
- You have already had at least one injection of the study drug, Daromun, directly into your tumor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an injected medicine placed directly into melanoma tumors before surgery can improve outcomes for melanoma that has spread to nearby lymph nodes/skin but can still be fully removed. It aims to shrink the cancer and reduce the chance it comes back after surgery.
This trial tests whether injecting immune-boosting drugs directly into melanoma tumors, alongside the immunotherapy pembrolizumab, can help people whose cancer has not responded to previous immunotherapy. It aims to shrink tumors and improve treatment outcomes.
This trial is testing a combination of two oral medications (darovasertib and crizotinib) after standard local treatment for high-risk uveal melanoma that has not spread. The goal is to see if this treatment can reduce the risk of the cancer coming back.
This trial tests a new drug called LM103 for people with advanced melanoma who have already tried several standard treatments, including immunotherapy. The goal is to see if LM103 can help shrink tumors when other treatments have stopped working.
This study tests a new way of giving a combination of two immunotherapy drugs (ipilimumab and nivolumab) for advanced melanoma. The drugs are given either into a vein or into the skin, to see if the skin injection works as well and causes fewer side effects.
This trial tests a combination of two immunotherapy drugs with standard chemotherapy (bevacizumab, albumin-bound paclitaxel, and carboplatin) for people with advanced acral or mucosal melanoma. The goal is to see if this combination can shrink tumors or slow the cancer's growth better than current treatments.
Hear when a new Injections Intralesional trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.